5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

pCPA – The Beginning of a Period of Uncertainty?

March 27, 2020
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights

 

Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation.


The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations.  Highlights since the last update include:

  • 7 products completed CADTH review, for a total of 11 files under consideration;
  • 5 products initiated pCPA negotiations, for a total of 33 active negotiations;
  • 5 negotiations completed for a total of 302 completed negotiations;
  • 1 negotiation closed, for a total of 49 closed negotiations; and
  • 1 file was closed without negotiation, for a total of 74 declined negotiations.

 

Files Under pCPA Consideration

 

7 new drug products received a CDEC recommendation or pERC notification to implement in February 2020, for a total of approximately 11 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Rinvoq Upadacitinib AbbVie Rheumatoid Arthritis Conditional
Kadcyla Trastuzumab Emtansine Hoffmann-La Roche Early Breast Cancer Reimburse
Libtayo Cemiplimab Sanofi Genzyme Cutaneous Squamous Cell Carcinoma Conditional
Trintellix Vortioxetine hydrobromide Lundbeck Major depressive disorder Conditional
Vyndaqel Tafamidis Pfizer Transthyretin-Mediated Amyloidosis Conditional
Lorbrena Lorlatinib Pfizer Non-Small Cell Lung Cancer (NSCLC) Do not reimburse
Tecentriq Atezolizumab Hoffmann-La Roche Small Cell Lung Cancer (SCLC) Do not reimburse

 

Negotiation Initiation

 

The pCPA initiated 5 new negotiations since the last update, for a total of 33 active negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Initiate
Botox onabotulinumtoxinA Allergan Migraine, chronic 17 Oct 19 121 days
Verkazia cyclosporine Santen Severe vernal keratoconjunctivitis, pediatric 18 Nov 19 89 days
Revestive teduglutide Shire Short Bowel Syndrome (SBS), pediatrics 19 Nov 19 88 days
Takhzyro lanadelumab Shire Hereditary angioedema, prevention 19 Nov 19 88 days
Lutathera lutetium 177 dotatate Advanced Accelerator Applications gastroenteropancreatic neuroendocrine tumors (GEP-NETs) N/A N/A

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Signals Decoded:

Both Botox and Revestive are back in negotiations for new indications, while talks on Lutathera have been reactivated, after being closed without an agreement in December 2019.

 

 

Completed

 

The pCPA completed 5 negotiations since the last update for a total of 302 completed negotiations.

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Truxima rituximab Teva rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma Sep 19 153 days
Emerade epinephrine bitartrate Bausch Health emergency treatment of anaphylactic reactions Aug 19 184 days
Bosulif bosutinib Pfizer chronic myeloid leukemia Aug 19 184 days
Xtandi enzalutamide Astellas high risk non-metastatic castrate resistant prostate cancer Jul 19 215 days
Kuvan sapropterin dihydrochloride BioMarin Phenylketonuria May 17 1,006 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Signals Decoded:

February saw the completion of the first rituximab biosimilar negotiation, as well as Kuvan, which had been in negotiations for over two-and-a-half years.

 

 

Closed

 

The pCPA closed 1 negotiation since the last update for a total of 49 closed negotiations.

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Vizimpro dacomitinib Pfizer locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations Aug 19 184 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

Not Negotiated

 

The pCPA declined negotiation on 1 file since the last update for a total of 74 declined negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Decision*
Nerlynx neratinib Knight Therapeutics Hormone Receptor Positive Breast Cancer 20 Dec 19 57 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
New pCPA Website & Available Data
NEXT POST →
MORSE Consulting Strengthens HTA Strategy and Payer Expertise

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
pCPA - The Beginning of a Period of Uncertainty?